Akeso's Ivonescimab Shows Promising Results In Phase III Trial For Advanced Lung Cancer Treatment

(RTTNews) - Akeso Inc. announced that its PD-1/VEGF bispecific antibody, ivonescimab, in combination with chemotherapy, has demonstrated strongly positive results in the Phase III clinical trial (AK112-306/HARMONi-6) for first-line treatment of advanced squamous non-small cell lung cancer or sq-NSCLC.

The Independent Data Monitoring Committee or IDMC declared that the study had met its primary endpoint of progression-free survival at the first pre-specified interim analysis. The results of HARMONi-6 study are both statistically significant and clinically meaningful, the company said in a statement.

Data from the HARMONi-6 study show that, in the intention-to-treat population, ivonescimab plus chemotherapy decisively beat tislelizumab plus chemotherapy in terms of progression-free survival.

The company noted that the ivonescimab combination showed clinically meaningful progression-free survival benefits in both PD-L1-positive and PD-L1-negative populations.

Ivonescimab demonstrated a favorable safety profile, with no new safety signals identified. The incidence of treatment related serious adverse events and the incidence of bleeding events of grade 3 or higher were comparable to those of the control group.

For More Such Health News, visit rttnews.com.